YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Methylin


AddThis Social Bookmark Button

Injured by Methylin?

Black Box Warning Recommended
On February 9, 2006, an FDA panel voted to recommend a black box warning for Methylin and other drugs prescribed to treat attention deficit hyperactivity disorder (ADHD or ADD).  The Food and Drug Administration scientific committee voted 8-7 to add a black box warning, the agency's strongest, to the labels of five drugs in the class including Methylin, Ritalin, Concerta, Adderall and Metadate.

Deaths Reported to the FDA
The FDA had requested a review by the panel to evaluate ways of studying the ADHD drugs because of its data suggesting a link between the drugs and the risk of sudden death and serious cardiovascular problems including heart attacks, stroke, hypertension, palpitations and arrhythmia.  The agency reported 25 deaths between 1999 and 2003 which may be related to the ADHD drugs included in the warning.  Nineteen of the 25 deaths were children.  There were 54 cases of serious cardiovascular problems reported in children and adults.

About Methylin
Methylin contains Methylphenidate (MPH), which is an amphetamine-like stimulant that is found in numerous ADHD drugs.  Methylin, Ritalin, Concerta and Metadate all contain Methylphenidate.  Other drugs containing Methylphenidate include Rubifen and Focaline.  Methylphenidate is a central nervous system (CNS) stimulant which is thought to have a calming effect on some children with ADHD.  It is also thought to reduce impulsive behavior and acting out. It is said to increase concentration in children and adults with ADHD.  Adderall contains amphetamines. 

Legal Help for Methylin Victims

If you or a loved one took Methylin or another ADHD drug and experienced cardiovascular side effects or sudden death, please fill out the form at the right for a free case evaluation from a qualified dangerous drugs attorney.
MethylinRSS Feed

ADHD drugmakers must tell of risks

Feb 23, 2007 | SOUTH FLORIDA SUN-SENTINEL
Federal officials told the makers of Ritalin, Adderall, Strattera and all other drugs for treatment of attention deficit hyperactivity disorder, or ADHD, on Wednesday to come up with new pamphlets to explain the potential risks of the drugs to patients and parents. The announcement came almost a year after panels of Food and Drug Administration advisers recommended that informational guides be provided to consumers. There are 15 drugs to treat ADHD, including extended-release, patch and...

Government wants further ADHD drug warnings

Feb 22, 2007 | Baltimore Sun
The makers of Ritalin, Adderall, Strattera and other drugs treating attention-deficit hyperactivity disorder were advised by the government Wednesday to give patients and their parents an additional warning that those medicines could cause serious psychiatric and heart problems, including sudden death. Patients would receive with their prescriptions two-page "medication guides" that warn about possible side effects and urge them to notify doctors immediately after any sign of heart...

ADHD drug makers to warn of side effects

Feb 21, 2007 | AP
Drugs prescribed to treat attention deficit hyperactivity disorder will include guides to alert patients and parents of the risks of mental and heart problems, including sudden death. The Food and Drug Administration said Wednesday that it directed the manufacturers of Ritalin, Adderall, Strattera and all other ADHD drugs to develop the guides. In May 2006, the agency told manufacturers to revise the labels of the drugs to reflect concerns about the cardiovascular and psychiatric problems. ...

Drug makers to add warnings to ADHD pills

Feb 21, 2007 | AP
Drugs prescribed to treat attention deficit hyperactivity disorder will include guides to alert patients and parents of the risks of mental and heart problems, including sudden death. The Food and Drug Administration said Wednesday that it directed the manufacturers of Ritalin, Adderall, Strattera and all other ADHD drugs to develop the guides. In May 2006, the agency told manufacturers to revise the labels of the drugs to reflect concerns about the cardiovascular and psychiatric problems. ...

ADHD Drugs to Get New Warnings

Feb 21, 2007 | NewsInferno.com
The U.S. Food and Drug Administration (FDA) announced today that it is ordering all manufacturers of attention deficit hyperactivity disorder (ADHD) medication to develop Patient Medication Guides to warn patients of potentially serious side effects. The most significant warnings will be related to adverse psychiatric symptoms and to cardiovascular risks. “Medicines approved for the treatment of ADHD have real benefits for many patients but they may have serious risks as well,”...

More Methylin News

Methylin
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Did you (or injured party) experience any of the following:






Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News